Singapore Health Regulatory Updates – October 8‑14, 2026

Recall of Clonotril (Clonazepam) 0.5 Tablet 0.5 mg

The Health Sciences Authority announced a Class 2, retail-level recall of multiple batches of Clonotril 0.5 Tablet 0.5 mg supplied by Goldplus Universal Pte Ltd. The recall was initiated due to out-of-specification results observed during a stability study. Hospitals, clinics, and pharmacies have been instructed to stop supplying the affected batches and return remaining stocks to the company. Read more

Regulatory Structural Changes and AI Initiatives

At the Inaugural Health Regulatory Conference 2026, the HSA announced upcoming structural and operational transitions following the passage of the HSA (Amendment) and Other Matters Bill. Beginning 1 November 2026, regulatory functions from the Ministry of Health will transition under HSA to establish an integrated regulatory framework covering health products, services, and health information. HSA also highlighted initiatives to enhance regulatory workflows for health technologies, including new AI-driven tools for medical device classification and adverse event coding, as well as prioritized reviews for products undergoing local clinical development. Read more

Partnerships to Accelerate Healthcare Innovations

The Health Sciences Authority (HSA) announced three initiatives to accelerate patient access to innovative healthcare products and therapies. These include a Regulatory Innovation Corridor established with the UK MHRA for AI-driven drug development and clinical trials, streamlined regulatory review processes halving approval times for selected lower-risk Phase 3 clinical trials, and a joint ACE-HSA Priority Track allowing concurrent regulatory evaluation and health technology assessment starting November 2026. In addition, Singapore's broader health regulatory functions will be consolidated under HSA in phases starting 1 November 2026. Read more